Endocrine therapy (ET) such as tamoxifen and/or aromatase inhibitors reduces the risk of breast cancer recurrence in patients with estrogen receptor positive tumors (60% of breast cancer)2, but is often accompanied by complaints of cognitive impairment (independent of chemotherapy)3–5. This evidence concerns the gene CYP19A1 and breast cancer.